• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 21Estimated odds ratios for withdrawals due to adverse events (ARBs vs. ACEIs)

StudyOdds ratioLn(OR)Standard errorStudy type
Avanza et al., 2000800.2635-1.33371.5177OBS
Verdecchia et al., 2000990.4500-0.79850.8074OBS
Mallion et al., 1995560.9899-0.01020.5749RCT
Tikkanen et al., 1995750.4176-0.87310.4984RCT
Townsend et al., 1995760.7561-0.27960.4590RCT
Black et al., 1997380.8950-0.11090.4526RCT
Roca-Cusachs et al., 1997690.4128-0.88490.6004RCT
Mimran et al., 1998593.18951.15991.1635RCT
Elliott, 1999431.00000.00001.4169RCT
Karlberg et al., 1999510.6606-0.41450.4115RCT
Naidoo et al., 1999610.9827-0.01750.8236RCT
Neutel et al., 1999630.0602-2.80971.0644RCT
Lacourciere et al., 2000532.00000.69311.2410RCT
McInnes et al., 2000580.4574-0.78220.3964RCT
Mogensen et al., 2000600.9688-0.03171.0158RCT
Shand et al., 2000940.2903-1.23681.6749RCT
Amerena et al., 2002350.4808-0.73240.6187RCT
Coca et al., 2002400.6850-0.37830.9227RCT
Cuspidi et al., 20021090.4700-0.75500.5116RCT
De Rosa et al., 2002410.1159-2.15501.5395RCT
Barnett et al., 2004370.6667-0.40550.3215RCT
Malacco et al., 2004260.3854-0.95350.3975RCT
Koylan et al., 2005890.0174-4.05311.4315RCT
Schram et al., 2005323.00001.09861.1952RCT
Deyneli et al., 2006420.3067-1.18201.6833RCT
Fogari, et al., 2006470.4872-0.71910.8809RCT
Lacourciere et al., 20061060.5098-0.67380.3633RCT
Spoelstra-de Man et al., 2006333.00001.09861.1952RCT
Tedesco et al., 2006340.3937-0.93220.8461RCT
Xu et al., 20071010.2086-1.56731.5627RCT
Fogari et al., 2008240.1967-1.62611.1030RCT
Hermida et al., 2008252.00000.69311.2353RCT
Kloner et al., 2008520.3561-1.03261.6388RCT
Menne et al., 2008280.8063-0.21540.7947RCT
Zhu et al., 2008780.1869-1.67731.5709RCT
Nakamura et al., 2009620.1925-1.64791.5738RCT

Ln(OR) = natural log of odds ratio; OBS = observational study; RCT = randomized controlled trial

From: Results

Cover of Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update
Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update [Internet].
Comparative Effectiveness Reviews, No. 34.
Sanders GD, Coeytaux R, Dolor RJ, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.